STRAP
Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. The company was founded in 2009 and is based in Herlev, Denmark.
STRAP (STRAP) - Net Assets
Latest net assets as of June 2025: Dkr18.06 Million DKK
Based on the latest financial reports, STRAP (STRAP) has net assets worth Dkr18.06 Million DKK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr18.85 Million) and total liabilities (Dkr789.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr18.06 Million |
| % of Total Assets | 95.81% |
| Annual Growth Rate | -58.03% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 172.41 |
STRAP - Net Assets Trend (2020–2024)
This chart illustrates how STRAP's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for STRAP (2020–2024)
The table below shows the annual net assets of STRAP from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Dkr19.25 Million | +35.15% |
| 2023-12-31 | Dkr14.24 Million | -65.24% |
| 2022-12-31 | Dkr40.97 Million | +338.74% |
| 2021-12-31 | Dkr9.34 Million | -98.49% |
| 2020-12-31 | Dkr620.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to STRAP's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 151591200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr12.99 Million | 67.49% |
| Common Stock | Dkr6.26 Million | 32.51% |
| Total Equity | Dkr19.25 Million | 100.00% |
STRAP Competitors by Market Cap
The table below lists competitors of STRAP ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SPARTOO SAS EO -02
F:7ZP
|
$1.48 Million |
|
Universe Pharmaceuticals Inc
NASDAQ:UPC
|
$1.48 Million |
|
Mohit Industries Limited
NSE:MOHITIND
|
$1.48 Million |
|
Alakasa Industrindo Tbk
JK:ALKA
|
$1.49 Million |
|
Universal PropTech Inc
PINK:UPIPF
|
$1.48 Million |
|
Gamla Harel Residential Real-Estate Ltd
TA:GMLA
|
$1.48 Million |
|
MSCM Holdings Bhd
KLSE:0041
|
$1.48 Million |
|
HB Stockholdings Limited
NSE:HBSL
|
$1.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in STRAP's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 14,242,000 to 19,248,000, a change of 5,006,000 (35.1%).
- Net loss of 298,000 reduced equity.
- New share issuances of 5,306,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr-298.00K | -1.55% |
| Share Issuances | Dkr5.31 Million | +27.57% |
| Other Changes | Dkr-2.00K | -0.01% |
| Total Change | Dkr- | 35.15% |
Book Value vs Market Value Analysis
This analysis compares STRAP's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.04x to 1.24x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Dkr17884.11 | Dkr642.00 | x |
| 2021-12-31 | Dkr267.41 | Dkr642.00 | x |
| 2022-12-31 | Dkr1161.76 | Dkr642.00 | x |
| 2023-12-31 | Dkr406.91 | Dkr642.00 | x |
| 2024-12-31 | Dkr518.46 | Dkr642.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently STRAP utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-1.55%) is above the historical average (-1453.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -102.05% | 0.00% | 0.00x | 1.33x | Dkr-695.30 Million |
| 2021 | -6708.84% | -1731.11% | 0.21x | 18.55x | Dkr-627.47 Million |
| 2022 | -269.91% | 0.00% | 0.00x | 1.39x | Dkr-114.69 Million |
| 2023 | -182.90% | 0.00% | 0.00x | 1.36x | Dkr-27.47 Million |
| 2024 | -1.55% | 0.00% | 0.00x | 1.22x | Dkr-2.22 Million |
Industry Comparison
This section compares STRAP's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $68,130,500
- Average return on equity (ROE) among peers: -74.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| STRAP (STRAP) | Dkr18.06 Million | -102.05% | 0.04x | $1.48 Million |
| Gubra A/S (GUBRA) | $80.01 Million | 15.86% | 1.44x | $338.83 Million |
| Pharma Equity Group A/S Cl A (PEG) | $56.25 Million | -164.74% | 3.65x | $13.66 Million |